Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
The index date (baseline) is defined as the date of alpelisib initiation. The study period is the period from the index date up to the most recent data available at the time of the cut-off date.
The maximum follow-up was 187 weeks.
Age
2–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient (adult or pediatric) is ≥ 2 years of age
Patient has a physician confirmed/documented diagnosis of PROS
Patient has a documented evidence of a mutation in the PIK3CA gene
Patient's condition was assessed by the treating physician as severe or life threatening and treatment was deemed necessary
Patient has been treated with at least one dose of alpelisib, initiated on or before 23-Sep-2019 (i.e. at least 24 weeks before the cut-off date of the 09-Mar-2020)
Patient has medical chart history available during enrollment in the Novartis MAP
